Itamar Medical Launches Enhancements to WatchPAT™ Product Line at SLEEP 2021
- Enables Patient Smartphone App to Collect Subjective Data at Time of Test
- Designed to Improve the Quality and Efficiency of Home Sleep Diagnostics
CAESAREA, Israel, June 07, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced two enhancements to its WatchPAT™ product line that the Company plans to unveil on June 11 during the Virtual SLEEP 2021 Conference, a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society.
“These product enhancements reflect our commitment to continuous improvement of the sleep patient pathway by leveraging Itamar’s digital health platform to deliver increased home sleep testing efficiency, broader information access beyond the Apnea Hypopnea Index (AHI) and improving the quality of sleep clinics’ operations around home sleep diagnostics,” said Gilad Glick, President and Chief Executive Officer.
WatchPAT™ ONE with SleepPath™
For the first time, subjective data can be collected from patients through the WatchPAT smartphone app, both before and after the home sleep test. This new service, WatchPAT™ with SleePath™, will be offered to sleep clinics and will be customizable based on the specific needs of the sleep clinic and their patients. This new service gives sleep health providers simple and easy access to digital documentation in one report that combines sleep study metrics and patient self-reported data, replacing traditional paper documentation.
The WatchPAT™ONE-M, an enhancement to the Company’s innovative WatchPAT™ONE, enables sleep physicians to order multi-night test and follow-up with their patients after each night of testing to determine if further testing would be beneficial. This is most relevant in situations where the need for further evaluation become apparent after the first night of testing or if new information provided by the patient raises concerns and additional testing could be critical.
“As our WatchPAT™ technology becomes increasingly more predominant in sleep disorder diagnostics, we look forward to leveraging our growing customer base to transition our WatchPAT™ app into an active communication tool for patients and their physicians. The addition of WatchPAT™ ONE-M is expected to support a higher level of interaction between sleep physicians and their patients, as it provides an opportunity to leverage patient feedback in parallel with the sleep test, deliver one comprehensive report, and enable physicians to follow-up with their patients more effectively,” added Glick.
“We are excited with the announcement of WatchPAT™ with SleePath™ and WatchPAT™ONE-M multi-night capability. These advancements will further simplify the sleep diagnosis process and are a critical step towards more personalized sleep diagnostics as so many things impact sleep, and not all nights are the same,” said Dr. Matthew Schmitt, Clinical Governance Council Chief of Sleep Medicine, Piedmont Healthcare.
About Itamar Medical Ltd.
Itamar Medical is a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders. Itamar Medical commercializes a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the core sleep, cardiology and direct to consumer markets. Itamar Medical offers a Total Sleep Solution to help physicians provide comprehensive sleep apnea management in a variety of clinical environments to optimize patient care and reduce healthcare system costs. The Company’s key product, WatchPAT, is commercially available within major markets including the US, Japan, and Europe. Itamar Medical is a public company traded on the Nasdaq and on the Tel Aviv Stock Exchanges, and is based in Caesarea, Israel with U.S. headquarters based in Atlanta, GA. For additional information visit www.itamar-medical.com.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Statements preceded by, followed by, or that otherwise include the words "believes", "expects", "anticipates", "intends", "estimates", "plans", and similar expressions or future or conditional verbs such as "will", "should", "would", "may" and "could" are generally forward-looking in nature and not historical facts. For example, when we discuss our WatchPAT™ technology becoming increasingly more predominant in sleep disorder diagnostics we are using forward looking statements. Because such statements deal with future events, they are subject to various risks, uncertainties and assumptions, including events and circumstances out of Itamar Medical's control and actual results, expressed or implied by such forward-looking statements, could differ materially from Itamar Medical's current expectations. Factors that could cause or contribute to such differences include, but are not limited to, risks, uncertainties and assumptions discussed from time to time by us in reports filed with, or furnished to, the U.S. Securities and Exchange Commission (“SEC”) and the Israel Securities Authority (“ISA”), including our latest Annual Report on Form 20-F which is on file with the SEC and the ISA. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Itamar Medical Investor Relations Contact (U.S.)